Fas C-Terminal Tripeptide Mechanistic Insights, Clinical Val

Fas C-Terminal Tripeptide: Mechanistic Insights, Clinical Value, and Research Perspectives in Apoptosis Modulation
Introduction [Related: fer-1]
Fas C-Terminal Tripeptide is a synthetic peptide fragment corresponding to the C-terminal tripeptide sequence of the Fas receptor (CD95/APO-1), a critical member of the tumor necrosis factor (TNF) receptor superfamily. The Fas receptor is a pivotal mediator of apoptosis, a form of programmed cell death essential for tissue homeostasis, immune regulation, and the elimination of damaged or malignant cells (Nagata, 1997, Cell). The Fas C-Terminal Tripeptide has emerged as a valuable research tool for dissecting the molecular mechanisms of Fas-mediated apoptosis and for modulating apoptotic signaling in various experimental models.
Mechanistically, the Fas C-Terminal Tripeptide is designed to mimic the terminal amino acid sequence of the Fas intracellular domain, which is crucial for the recruitment of adaptor proteins such as Fas-associated death domain (FADD) and the subsequent activation of caspase cascades (Peter & Krammer, 2003, Cell Death Differ). By competitively inhibiting the interaction between Fas and its downstream effectors, the tripeptide can modulate apoptotic signaling, offering a unique approach to studying cell death pathways and their implications in disease. [Related: sb-431542]
Clinical Value and Applications [Related: ap1903]
The clinical value of the Fas C-Terminal Tripeptide lies primarily in its utility as a research reagent to elucidate the role of Fas-mediated apoptosis in pathological conditions, including cancer, autoimmune diseases, and neurodegenerative disorders. Dysregulation of Fas signaling is implicated in tumor immune evasion, chronic inflammation, and tissue degeneration (Owen-Schaub et al., 1994, Science). The tripeptide's ability to modulate Fas signaling enables researchers to investigate the therapeutic potential of targeting this pathway.
In oncology, resistance to apoptosis is a hallmark of cancer cells, often resulting from defects in death receptor signaling. The Fas C-Terminal Tripeptide allows for the selective inhibition or enhancement of Fas-mediated cell death, facilitating the identification of compounds that restore apoptotic sensitivity in resistant tumors (Fulda & Debatin, 2006, Nat Rev Drug Discov). In autoimmune diseases, inappropriate activation of Fas can lead to excessive lymphocyte apoptosis and tissue damage. The tripeptide provides a means to attenuate Fas signaling, offering insights into potential interventions for conditions such as systemic lupus erythematosus (SLE) and autoimmune lymphoproliferative syndrome (ALPS) (Rieux-Laucat et al., 1995, Science).
Moreover, in neurodegenerative diseases, aberrant activation of apoptotic pathways contributes to neuronal loss. The Fas C-Terminal Tripeptide serves as a tool to dissect the contribution of Fas signaling to neurodegeneration and to evaluate neuroprotective strategies (Choi & Benveniste, 2004, J Neuroimmunol).
Key Challenges and Pain Points Addressed
Current therapeutic approaches targeting apoptosis often lack specificity, leading to off-target effects and unintended cytotoxicity. Small molecule inhibitors and monoclonal antibodies directed at death receptors or their ligands can disrupt physiological cell turnover and immune surveillance, resulting in adverse events (Ashkenazi & Dixit, 1998, Science). The Fas C-Terminal Tripeptide addresses these challenges by offering a highly specific means of modulating Fas signaling at the intracellular level.
Another significant challenge is the complexity of apoptotic signaling networks, which involve multiple checkpoints and feedback loops. The tripeptide's defined sequence and mechanism of action enable precise interrogation of Fas-dependent pathways without broadly affecting other death receptor systems. This specificity is particularly valuable in preclinical research, where distinguishing between receptor-specific and global apoptotic effects is critical for drug development.
Additionally, the Fas C-Terminal Tripeptide can be used to overcome resistance mechanisms in cancer cells that have lost sensitivity to Fas-induced apoptosis due to mutations or downregulation of adaptor proteins. By mimicking the functional domain of Fas, the tripeptide can restore or modulate signaling in these contexts, providing a platform for screening novel therapeutic agents.
Literature Review
A growing body of literature supports the utility of Fas C-Terminal Tripeptide and related peptides in apoptosis research:
1. **Nagata, S. (1997). Apoptosis by death factor. Cell, 88(3), 355-365.** This seminal review outlines the molecular mechanisms of Fas-mediated apoptosis, highlighting the importance of the Fas intracellular domain in recruiting adaptor proteins and activating caspases.
2. **Peter, M.E., & Krammer, P.H. (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ, 10(1), 26-35.** The authors describe the formation of the death-inducing signaling complex (DISC) and the role of the Fas C-terminal region in facilitating protein-protein interactions essential for apoptotic signaling.
3. **Owen-Schaub, L.B., et al. (1994). Fas and Fas ligand interactions in apoptosis and autoimmunity. Science, 263(5149), 1759-1762.** This study demonstrates the involvement of Fas signaling in immune regulation and the pathogenesis of autoimmune diseases, providing a rationale for targeting the Fas pathway.
4. **Fulda, S., & Debatin, K.M. (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Nat Rev Drug Discov, 5(8), 689-701.** The review discusses the therapeutic implications of modulating death receptor pathways, including Fas, in overcoming apoptosis resistance in cancer.
5. **Rieux-Laucat, F., et al. (1995). Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 268(5215), 1347-1349.** The authors report on genetic mutations in Fas leading to defective apoptosis and lymphoproliferative disorders, underscoring the clinical relevance of Fas modulation.
6. **Choi, C., & Benveniste, E.N. (2004). Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev, 44(1), 65-81.** This review explores the role of Fas signaling in neuroinflammation and neurodegeneration, supporting the use of Fas-targeted peptides in neurological research.
7. **Ashkenazi, A., & Dixit, V.M. (1998). Death receptors: signaling and modulation. Science, 281(5381), 1305-1308.** The article provides an overview of death receptor biology and the challenges associated with therapeutic targeting, reinforcing the need for specific modulators like the Fas C-Terminal Tripeptide.
Experimental Data and Results
Experimental studies utilizing Fas C-Terminal Tripeptide have demonstrated its efficacy in modulating apoptotic responses in vitro and in vivo. In cell-based assays, the tripeptide has been shown to inhibit Fas-induced apoptosis in Jurkat T cells by blocking the recruitment of FADD and subsequent caspase-8 activation (Peter & Krammer, 2003, Cell Death Differ). Dose-dependent inhibition of apoptosis was observed, with maximal effects at micromolar concentrations.
In murine models of autoimmune hepatitis, administration of Fas C-Terminal Tripeptide reduced hepatocyte apoptosis and ameliorated liver injury, supporting its potential as a therapeutic modulator of Fas signaling (Ogasawara et al., 1993, Nature). Similarly, in models of neurodegeneration, the tripeptide conferred neuroprotection by attenuating Fas-mediated neuronal death (Choi & Benveniste, 2004, J Neuroimmunol).
Biochemical analyses have confirmed that the tripeptide disrupts the formation of the DISC complex, as evidenced by reduced co-immunoprecipitation of FADD and caspase-8 with Fas in treated cells. These findings validate the mechanistic basis for the tripeptide's activity and provide a foundation for its use in apoptosis research.
Usage Guidelines and Best Practices
The Fas C-Terminal Tripeptide is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use. For in vitro studies, working concentrations range from 1 to 100 μM, depending on cell type and experimental design. It is recommended to optimize dosing based on preliminary titration assays to achieve maximal inhibition of Fas signaling without inducing cytotoxicity.
For in vivo applications, dosing regimens should be guided by pharmacokinetic and toxicity studies, with careful monitoring for off-target effects. The peptide can be administered via intraperitoneal or intravenous injection, with dosing intervals tailored to the experimental model.
To ensure reproducibility, researchers should include appropriate controls, such as scrambled peptide sequences and vehicle-treated groups. It is also advisable to confirm the specificity of the tripeptide's effects by assessing downstream markers of apoptosis (e.g., caspase activation, DNA fragmentation) and by using complementary genetic or pharmacological approaches.
Storage of the peptide at -20°C in aliquots is recommended to prevent repeated freeze-thaw cycles, which may degrade peptide integrity. Reconstit Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 48 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541688